174 related articles for article (PubMed ID: 33982418)
1. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
[TBL] [Abstract][Full Text] [Related]
2. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
Perrino PJ; Colucci SV; Apseloff G; Harris SC
Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743
[TBL] [Abstract][Full Text] [Related]
4. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
[TBL] [Abstract][Full Text] [Related]
5. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
[TBL] [Abstract][Full Text] [Related]
6. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
7. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
[TBL] [Abstract][Full Text] [Related]
8. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
[TBL] [Abstract][Full Text] [Related]
9. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
Franke RM; Morton T; Devarakonda K
Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.
Schoedel KA; Gillespie M; Levy-Cooperman N; Shram MJ; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):32-39. PubMed ID: 29723441
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
[TBL] [Abstract][Full Text] [Related]
14. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
15. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
[TBL] [Abstract][Full Text] [Related]
18. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
Meske D; Kopecky EA; Passik S; Shram MJ
J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
